Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 84 EV-to-OCF is 24.74 as of Aug. 08, 2026, which is 45% below its 10-year median of 45.08. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €201.33 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 80.05% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's EV-to-OCF or its related term are showing as below:
CHIX:DIMp'
s EV-to-OCF Range Over the Past 10 Years
Min: 20.54 Med: 45.08 Max: 217.22
Current: 24.3
During the past 13 years, the highest EV-to-OCF of Sartorius Stedim Biotech was 217.22. The lowest was 20.54. And the median was 45.08.
CHIX:DIMp's EV-to-OCF is ranked worse than 80.05% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.835
vs CHIX:DIMp: 24.30
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sartorius Stedim Biotech's PE Ratio (TTM) for today is calculated as:
Sartorius Stedim Biotech's share price for today is €172.65.
Sartorius Stedim Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sartorius Stedim Biotech EV-to-OCF Related Terms
Sartorius Stedim Biotech EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: EV-to-OCF Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's EV-to-OCF falls into.
Sartorius Stedim Biotech's current Enterprise Value is €19,515 Mil.
Sartorius Stedim Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €789 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a EV-to-OCF of 24.74 as of Aug. 08, 2026. This is 45% below median its historical median of 45.08. Over the past decade, Sartorius Stedim Biotech's EV-to-OCF has ranged from 20.54 to 217.22. According to the industry distribution chart, Sartorius Stedim Biotech ranks #682 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 80%.
Is Sartorius Stedim Biotech's EV-to-OCF too high?
Sartorius Stedim Biotech's current EV-to-OCF of 24.74 is 45% below median its 10-year median of 45.08. Over the past 10 years, this metric has ranged from a low of 20.54 to a high of 217.22. The Medical Devices & Instruments industry median EV-to-OCF is 7.84. Sartorius Stedim Biotech's value of 24.74 is 215.8% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #682 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #682 out of 852 companies for EV-to-OCF. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median EV-to-OCF is 7.84. Sartorius Stedim Biotech's value of 24.74 is 215.8% above this benchmark. Historically, Sartorius Stedim Biotech's own EV-to-OCF has ranged from 20.54 to 217.22 over the past decade. While the company's 10-year median is 45.08 vs. the industry median of 7.84, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.84, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current EV-to-OCF of 24.74 is 215.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current EV-to-OCF is 24.74, which is 45% below median its own 10-year median of 45.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €201.33, compared to a current price of €172.65 — trading 14.2% below its estimated fair value. The current EV-to-OCF is 24.74, which is 45% below median its 10-year median of 45.08 and 215.8% above the Medical Devices & Instruments industry median of 7.84. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current EV-to-OCF is 24.74 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €172.65 is trading 14.2% below its estimated GF Value™ of €201.33.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
EV-to-OCF: 24.74 (45% below median its 10-year median of 45.08)
GF Value™: €201.33 vs. price of €172.65 (14.2% below fair value)
Industry Position: 215.8% above the Medical Devices & Instruments median (#682 of 852)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
